257 related articles for article (PubMed ID: 25980453)
1. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
2. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
3. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
4. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S
J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846
[TBL] [Abstract][Full Text] [Related]
6. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
7. [The role of biochemical markers with special regard to troponin, CK-MB, NT-proBNP as early biomarkers of cardiotoxicity among women after chemotherapy due to breast cancer].
Stachowiak P; Milchert-Leszczyńska M; Falco M; Polakowska M; Wojtarowicz A; Kaliszczak R; Safranow K; Kornacewicz-Jach Z
Przegl Lek; 2016; 73(6):359-63. PubMed ID: 29668198
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
[TBL] [Abstract][Full Text] [Related]
10. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
Ürun Y; Utkan G; Yalcin B; Akbulut H; Onur H; Oztuna DG; Şenler FC; Demirkazık A; İçli F
Exp Oncol; 2015 Mar; 37(1):53-7. PubMed ID: 25804233
[TBL] [Abstract][Full Text] [Related]
11. Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?
Roziakova L; Mistrik M; Batorova A; Kruzliak P; Bojtarova E; Dubrava J; Gergel J; Mladosievicova B
Cardiovasc Toxicol; 2015 Jul; 15(3):210-6. PubMed ID: 25287586
[TBL] [Abstract][Full Text] [Related]
12. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
13. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer.
Silva FB; Romero WG; Carvalho AL; Borgo MV; Amorim MH; Gouvea SA; Abreu GR
Braz J Med Biol Res; 2015 Feb; 48(2):154-60. PubMed ID: 25424369
[TBL] [Abstract][Full Text] [Related]
16. The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation.
Franeková J; Hošková L; Sečník P; Pazderník M; Kotrbatá M; Kubíček Z; Jabor A
Clin Chem Lab Med; 2016 Feb; 54(2):339-44. PubMed ID: 26351922
[TBL] [Abstract][Full Text] [Related]
17. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.
Bulten BF; Verberne HJ; Bellersen L; Oyen WJ; Sabaté-Llobera A; Mavinkurve-Groothuis AM; Kapusta L; van Laarhoven HW; de Geus-Oei LF
Cancer Chemother Pharmacol; 2015 Nov; 76(5):957-67. PubMed ID: 26400150
[TBL] [Abstract][Full Text] [Related]
18. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
19. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
20. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
